Unlock the secrets of your metabolism with a single breath. On this episode of the AWS Health Innovation Podcast, Mike Tarselli, Specialist Leader for HCLS Data & AI, explores the cutting-edge world of breath-based health tech with Daniel Tal Mor, Founder & CEO of Lumen. Discover how this innovative device is transforming the way we approach metabolic health, offering real-time insights through a simple smartphone app.How does Lumen's device measure metabolism?Lumen's innovative technology measures metabolism through a single breath, providing real-time data on whether the body is burning fat or carbs. This approach democratizes metabolic health monitoring, offering an accessible alternative to expensive hospital equipment.What inspired the creation of Lumen?Lumen was born from the combined expertise of twin PhDs, Michal and Merav, who specialized in cardiac arrhythmia. Their backgrounds in nutrition and endurance athletics, coupled with frustration over limited nutrition study data, led to the development of this revolutionary metabolic measurement tool.How does the Lumen device analyze breath?The device analyzes CO2, humidity, temperature, and airflow in exhaled breath to determine metabolic state. This sophisticated technology translates complex physiological processes into actionable insights for users seeking to optimize their health.How does Lumen leverage data for personalized health recommendations?With over 66 million metabolic measurements from 300,000+ customers, Lumen offers highly personalized health recommendations. The platform's ability to provide tailored interventions based on vast datasets sets a new standard in digital health coaching.What role does cloud technology play in Lumen's functionality?Lumen's cloud-based processing enables continuous algorithm improvement and personalization without hardware changes. This approach allows the platform to adapt to various user needs, from weight loss to athletic performance optimization.How does AI contribute to Lumen's health insights?Lumen's AI analyzes diverse data points to provide context-appropriate health recommendations. The company's collaboration with AWS facilitates large-scale data storage and processing, driving continuous improvements in metabolic science.What research partnerships is Lumen involved in?Lumen is partnering with universities and hospitals to advance metabolic health research. The company's unique at-home device enables novel studies, potentially reshaping our understanding of metabolism in various populations and conditions.What does Lumen envision for the future of personalized metabolic health?Lumen anticipates a growing focus on metabolic health, partly due to weight loss medication side effects. The company's ability to detect menstrual cycle phases and menopause onset through metabolic measurements showcases the potential for highly personalized health insights.To learn more about Lumen and their innovative metabolic health technology, visit https://www.lumen.me/. Use coupon code AWS for a special discount on a Lumen device.Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

The aging population is creating unprecedented challenges in senior care. In this episode of the AWS Health Innovation Podcast, Guy Spigelman, EMEA lead for Healthcare and Life Sciences Startups at AWS, speaks with Nevo Elmalem, Co-Founder & CTO of Sensi.ai. Sensi is on a mission to unleash growth, productivity, and purpose for home care agencies, empowering every senior to safely age in place through care intelligence.Sensi.AI's sophisticated audio AI platform transforms home care by predicting and detecting care events while maintaining privacy. It equips agencies with essential insights into senior health, enabling timely interventions and tailored care plans. This reduces hospitalizations, enhances caregiver-client relationships, and prolongs service durations, allowing seniors to stay at home longer. How did personal experiences shape the founding of Sensi.ai?Nevo Elmalem's journey to founding Sensi.ai was inspired by two powerful personal experiences. These stories highlighted the critical need for holistic assessment and safety in care environments, driving the innovation behind Sensi.ai's technology.How does Sensi.ai's technology enable aging in place?Sensi.ai's audio-based monitoring system allows seniors to remain safely in their homes. Sensi's AI technology is trusted by home care agencies across the nation for its ability to identify over 100 critical insights, including early indicators of respiratory infections, UTIs, care resistance, cognitive shifts, and emergencies like falls. Our customers share how Sensi is preserving independence and quality of life for the older adults while also saving lives by enabling timely intervention. .What gives Sensi.ai a competitive edge in the eldercare market?Sensi's AI, powered by the home care industry’s largest proprietary dataset with over 1,000 years of audio data, offers unmatched precision, privacy, and comprehensiveness. Unlike traditional senior care technologies that rely on user input, Sensi operates continuously, requiring no action from seniors—an approach especially vital for emergencies and dementia care. By shifting from reactive to proactive care, Sensi enables agencies to craft personalized care plans and provide seamless support, even in caregivers' absence. This ensures consistent, tailored care for seniors while enhancing communication with families, caregivers, and healthcare providers for a holistic care experience.How did Sensi.ai approach startup challenges and funding?Nevo details Sensi.ai's lean approach to product development and funding. Their strategy of demonstrating traction before seeking VC investment proved successful, resulting in over $53 million raised to support their growth and innovation.Can you share examples of AI's impact on eldercare through Sensi.ai?Sensi benefits seniors, families, and care teams alike. It acts as a safety net by detecting medication errors, falls, cognitive decline, and predicting infections like UTIs or respiratory issues reducing hospitalizations. Additionally, it provides insights into caregiver-client dynamics for optimal match increasing caregiver retention. As a care copilot, Sensi supports home care agencies in delivering better care and driving growth.What technologies power Sensi.ai's eldercare solution?Sensi.ai leverages AWS services and combines hardware, IoT, and AI technologies. This innovative tech stack addresses the growing demand for effective, scalable eldercare solutions, positioning Sensi.ai at the forefront of the eldercare revolution.To learn more about Sensi.ai and their innovative approach to eldercare, visit their website at https://sensi.ai/.Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Transforming real-world medical data into actionable evidence in minutes, not years - this is the revolutionary approach of Atropos Health. On today's episode of the AWS Health Innovation Podcast, host Sanjit Misra has a fascinating conversation with Dr. Brigham Hyde, CEO and Co-Founder of Atropos Health. from technology developed and tested at Stanford, Atropos Health is reshaping the landscape of evidence-based medicine, providing on-demand evidence from real-world data to close critical gaps in healthcare and life sciences. Let's dive into how Atropos Health is elevating clinical outcomes, accelerating research, and driving operational efficiency.How did Atropos Health evolve from an academic project to an industry disruptor?Atropos Health's journey exemplifies the power of translating research into real-world impact. The company's mission to accelerate evidence generation aligns well with the growing demand for data-driven healthcare decision-making, showcasing how academic innovations can transform into practical solutions for the healthcare industry.What critical healthcare challenge does Atropos address?Atropos tackles the significant gap in high-quality evidence for many medical decisions. By rapidly generating real-world evidence, they aim to improve patient outcomes across diverse populations, including traditionally underrepresented groups, thus addressing a crucial need in healthcare decision-making.How does GENEVA OS™(Generative Evidence Acceleration Operating System) revolutionize healthcare research?Atropos Health’s GENEVA OS a critical infrastructure layer for the healthcare ecosystem that can rapidly, accurately, and transparently convert healthcare data into personalized evidence' streamlines complex data analysis and makes it accessible to non-technical users. This innovation significantly reduces the time and resources needed for healthcare research, potentially accelerating medical advancements and democratizing access to data-driven insights.What role does AI play in Atropos Heath's clinical insights generation?Chat RWD™, Atropos Healths' AI co-pilot, transforms clinical questions into real-world evidence studies in seconds. This technology has the potential to revolutionize point-of-care decision-making, enabling physicians to access personalized, evidence-based insights instantly, thereby enhancing the quality and efficiency of patient care.Can you provide examples of Atropos Health's real-world impact on patient care?Atropos Health's technology has demonstrated tangible benefits in clinical settings, from avoiding unnecessary tests to resolving treatment debates and improving shared decisionmaking. These case studies highlight the potential for data-driven approaches to improve healthcare efficiency and patient outcomes, showcasing the practical applications of their innovative platform.How does Atropos Health plan to expand its impact on global healthcare?I nternational expansion plans include addressing the need for diverse, representative medical evidence. By enabling global access to real-world data insights, they aim to reduce healthcare disparities and improve treatment efficacy worldwide, potentially transforming healthcare decision-making on a global scale.To learn more about how Atropos Health is revolutionizing healthcare decision-making with real-world data, visit their website at https://www.atroposhealth.com.Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

In this episode of the AWS Health Innovation Podcast, Yin He, Principal Business Development for Healthcare & Life Sciences Startups at AWS, explores the future of scientific research with Bogdan Knezevic, Co-Founder & CEO of Kaleidoscope Bio. Discover how their innovative software platform is transforming R&D by making it more collaborative, reproducible, and scalable across the life sciences industry.How is Kaleidoscope Bio revolutionizing R&D in the biotech and pharma industries?Kaleidoscope's platform streamlines R&D processes by integrating data from various sources, enhancing collaboration, and improving decision-making. This approach accelerates therapeutic development and helps companies reach clinical trials more efficiently.What role does data play in driving decisions in life sciences research?The Kaleidoscope platform aggregates critical information, allowing stakeholders to visualize and analyze data effectively. This empowers R&D leaders to make informed decisions, potentially reducing unnecessary costs and accelerating time-to-market for life-saving therapies.How does Kaleidoscope Bio cater to the diverse needs of different labs?Kaleidoscope offers customized product versions to accommodate varying technological infrastructures in life science companies. Their flexible approach ensures that both cutting-edge labs and those using basic tools can benefit from streamlined data management and improved collaboration.What design principles guide Kaleidoscope's platform development?Kaleidoscope prioritizes user-friendly interfaces to simplify complex workflows for scientists. Features like smart field mapping and one-click data highlighting demonstrate the platform's commitment to enhancing productivity in research environments.How does Kaleidoscope's platform help measure R&D efficiency and impact?The platform provides tools for assessing research productivity and identifying bottlenecks in the drug development process. This transparency enables both individual scientists and leadership to evaluate performance and optimize resource allocation.What inspired the creation of Kaleidoscope Bio?Bogdan Knezevic's background in genomics and biotech startups inspired Kaleidoscope's mission. The company's focus on solving fundamental R&D challenges reflects a deep understanding of the industry's needs and the potential for significant time and cost savings in scientific research.To learn more about Kaleidoscope Bio and their innovative R&D platform, visit kaleidoscope.bio.Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation.Please take a moment and let us know what you think of the podcast, access our feedback survey here.

Vijay Yanamadala, Chief Medical Officer at Sword Health and a dual-fellowship board-certified spinal neurosurgeon, discusses the future of musculoskeletal care. He reveals how Sword Health is breaking barriers by providing virtual therapy that reaches underserved communities. The use of AI for real-time tracking enhances personalized treatment plans, ensuring optimal recovery while reducing unnecessary surgeries by 60%. Additionally, Vijay emphasizes the importance of inclusivity and data security in virtual healthcare as they transform patient experiences.

In this engaging conversation, Brian Pepin, CEO of Rune Labs, shares his visionary work in precision medicine for neurodegenerative diseases. He discusses how Rune Labs is leveraging real-world data to transform therapy development, particularly for Parkinson's. The episode highlights the groundbreaking use of digital biomarkers for tracking disease progression and the innovative StrivePD system that enhances dopamine management via the Apple Watch. Pepin emphasizes patient empowerment through data accessibility and the collaboration needed to reshape healthcare.

Abdel Mahmoud, CEO and Co-Founder of Anterior, reveals his journey from immigrant to innovator in healthcare tech. He discusses how generative AI is set to alleviate the staggering $1 trillion administrative burden by transforming the prior authorization process. Exploring the intersection of healthcare and technology, he emphasizes the importance of streamlined user experiences and AI's ability to enhance clinician productivity. Mahmoud also shares insights on navigating the startup landscape and the pivotal role of partnerships in driving innovation.

In this engaging discussion, Adam Laing, Co-founder and Chief Scientific Officer of IMU Biosciences, shares how his company uses AI to decode the immune system. He explains the innovative technology behind measuring 80 million data points from blood samples, enabling personalized insights into health. The conversation highlights the potential of predictive immune profiling in tailoring treatments for diseases like cancer and autoimmune disorders. Laing also emphasizes the power of collaboration among multidisciplinary teams to drive breakthroughs in precision medicine.

Gabriel Jones, CEO and co-founder of Proprio, shares his expertise on how AI, computer vision, and augmented reality are revolutionizing surgery. He discusses Proprio's innovative approach to surgical precision through real-time 3D visualization and predictive analytics. With a diverse background in neurosurgery and engineering, Jones emphasizes the importance of interdisciplinary collaboration in driving innovation. The conversation also touches on the iterative product development process and the future of equitable healthcare access enhanced by advanced technologies.

In this episode of the AWS Health Innovation Podcast, host Yin He, Principal Business Development for Healthcare & Life Sciences Startups at AWS, sits down with Lindsay Edwards, CTO and President of Platform at Relation, a biotech company leveraging single-cell multi-omics, machine learning, and clinical insights to develop transformational medicines. 1. What is Relation's unconventional approach to drug discovery? Lindsay Edwards, a former musician turned drug hunter, embodies Relation's bold mission to transform drug discovery through multidisciplinary expertise bridging biology, data science, and creative intuition. Relation harnesses human genetic insights and single-cell data to pinpoint superior drug targets, addressing a critical bottleneck in pharmaceutical R&D. 2. How does Relation integrate lab experiments and machine learning? Relation's "Lab-in-the-Loop" approach tightly integrates wet lab experiments with machine learning, iteratively refining models that map genetic variation to disease mechanisms. Interdisciplinary collaboration between biologists, data scientists, and computational experts catalyzes this symbiosis of lab and AI. 3. How does Relation's initial focus in developing precision medicines for osteoporosis open opportunities in other therapuetic areas? By studying osteoblasts and genetic determinants of bone density, Relation aims to develop anabolic therapies driving new bone growth, addressing the large unmet need in osteoporosis with precision medicine. Their traction in osteoporosis shows how Relation can apply biological signals to improve machine learning modeling, uncover novel therapeutic targets. To learn more about Relation and their transformative approach to drug discovery, visit their website: https://www.relationrx.com/ Get in touch with AWS here to learn how we can help your organization accelerate healthcare innovation. Please take a moment and let us know what you think of the podcast, access our feedback survey here.